Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | PPM1B | O75688 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7472913 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17710064 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1297377 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1297896 | 1.00 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1650265 | 0.91 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31061871 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20928954 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1297555 | 0.89 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12265855 | 0.89 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL407796 | 0.86 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719369-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250257075-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250163072-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4551578-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4522596-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119654324-A | Novel compounds as hypoxia inducible factor 1 (HIF-1) inhibitors or Vascular Endothelial Growth Factor (VEGF) inhibitors and pharmaceutical compositions comprising the same | 株式会社次代生物科学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119497712-A | Indane derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024254161-A2 | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPS), METHODS OF USE AND METHODS OF MAKING | CELLORAM INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| EP-3049418-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | Vertex Pharmaceuticals Incorporated (US) | 2016-08-03 | — | — | EP | disclosed |
| WO-2016069976-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-06 | — | — | WO | disclosed |
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| WO-2015048245-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-02 | — | — | WO | disclosed |
| US-6399615-B1 | HALOGENATED BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE) -1-PIPERIDINES THAT BLOCK PHENOTYPIC CHANGE AND INTRACELLULAR PROCESSING OF RAS OF FARNESYL BUT NOT OF GERANYLGERANYL ACCEPTOR | SCHERING CORPORATION | 2002-06-04 | — | — | US | disclosed |
| EP-0991637-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6159984-A | Farnesyl protein transferase inhibitors | SCHERING CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0991637-A1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057945-A1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | RORC, RORB, RORA | CHRNB2 2346/4885CHRNA4 1129/4885CHRNB4 1917/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CHRNB2 4503/4885CHRNA4 4510/4885CHRNB4 4564/4885 |
| US-20250163072-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, FOLR1 | CHRNB2 4814/4885CHRNA4 4758/4885CHRNB4 4819/4885 |
| US-20250257075-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | CHRNB2 4853/4885CHRNA4 4877/4885CHRNB4 4871/4885 |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | CHRNB2 878/4885CHRNA4 1378/4885CHRNB4 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.